Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom
Alimentary Pharmacology & Therapeutics · 2026
DOI: 10.1111/apt.70400 ↗Kurz gefasst
Fachartikel in der Zeitschrift Alimentary Pharmacology & Therapeutics, 2026. Verfasst von Mohsin F Butt und 6 weiteren Autor:innen. Beteiligte Einrichtung: NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK. Hauptthemen laut MEDLINE: Irritable Bowel Syndrome, Analgesics, Opioid. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 62 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Tillotts Pharma.
Abstract (Originalsprache)
Background
The United Kingdom (UK) has one of the highest worldwide opioid prescription rates per capita. International guidelines caution against the use of opioids for chronic non‐malignant pain, including irritable bowel syndrome (IBS).
Aims
To study the prevalence and impact of regular opioid use among people with Rome IV IBS in community settings in the UK.
Methods
We collected demographic, quality of life (QoL), psychological symptoms, and healthcare utilisation data from 752 people with Rome IV IBS. Participants were recruited via electronic mailshot in July 2021 through ContactME‐IBS, a UK registry of persons diagnosed with IBS primarily by a general practitioner or gastroenterologist.
Results
Among participants, 148 (19.7%) reported taking an opioid regularly. The prevalence of opioid use did not vary across IBS subtypes ( p = 0.10). Disease‐specific and generic QoL were lower among opioid users than non‐users ( p < 0.001, both analyses). Compared with non‐users, a greater proportion of opioid users had anxiety or depression ( p < 0.001, both analyses) and greater overall activity impairment ( p < 0.001). The direct healthcare costs related to investigations ( p = 0.003), IBS‐related medications ( p < 0.001), and unplanned hospital attendances ( p < 0.001) were greater among participants who used opioids. Opioid users also expressed a greater willingness to accept the risk of death in return for a cure of IBS symptoms from a hypothetical medication ( p = 0.002).
Conclusion
Approximately one in five people with Rome IV IBS used opioids on a regular basis. Compared with non‐users, opioid users had worse QoL, greater psychological impairment, and higher direct healthcare costs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- NIHR Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, UK.
- Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine, University of Nottingham, Nottingham, UK.
- Leeds Institute of Medical Research at St. James's, University of Leeds, Leeds, UK.
- Leeds Gastroenterology Institute, St. James's University Hospital, Leeds, UK.
- County Durham and Darlington NHS Foundation Trust, Durham, UK.
- Manchester Academic Health Sciences Centre, UK.
ORCID-Profile: Mohsin F Butt, Christopher J Black, Alexander C Ford, Maura Corsetti
Förderung
- Tillotts Pharma
Zitieren
APA
Butt, M. F., Goodoory, V. C., Ng, C. E., Black, C. J., Ford, A. C., Corsetti, M., & Paine, P. (2026). Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom. Alimentary Pharmacology & Therapeutics. https://doi.org/10.1111/apt.70400
Vancouver
Butt MF, Goodoory VC, Ng CE, Black CJ, Ford AC, Corsetti M, et al. Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom. Alimentary Pharmacology & Therapeutics. 2026. doi:10.1111/apt.70400
BibTeX
@article{Butt2026,
author = {Butt, Mohsin F and Goodoory, Vivek C and Ng, Cho Ee and Black, Christopher J and Ford, Alexander C and Corsetti, Maura and Paine, Peter},
title = {Prevalence of Opioid Use and Associated Healthcare Outcomes in Rome IV Irritable Bowel Syndrome in the United Kingdom},
journal = {Alimentary Pharmacology & Therapeutics},
year = {2026},
doi = {10.1111/apt.70400}
}
EUVIMED